127561-10-8

Basic information

• Product Name: 1H-INDOLE,3-(2-BROMOETHYL)-5-FLUORO-
• Synonyms: 1H-INDOLE,3-(2-BROMOETHYL)-5-FLUORO-;3-(2-bromoethyl)-5-fluoro-1H-indole
• CAS NO: 127561-10-8
• Molecular Formula: C₁₀H₉BrFN
• Molecular Weight: 242.09
• Mol File: 127561-10-8.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-INDOLE,3-(2-BROMOETHYL)-5-FLUORO-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-INDOLE,3-(2-BROMOETHYL)-5-FLUORO-(127561-10-8)
• EPA Substance Registry System: 1H-INDOLE,3-(2-BROMOETHYL)-5-FLUORO-(127561-10-8)

Safety Data

• Hazardous Substances Data: 127561-10-8(Hazardous Substances Data)

Usage

Indole ring

A core structure consisting of a 5-membered nitrogen-containing aromatic ring

2-Bromoethyl substituent

A bromine atom attached to an ethyl group (-CH2CH3) attached to the indole ring at the 3rd position

5-Fluoro substituent

A fluorine atom attached to the indole ring at the 5th position

Organic synthesis

The process of creating new organic compounds by chemical reactions

Pharmaceutical research

The study of new drugs and their potential therapeutic applications

Building block

A starting material or intermediate used in the synthesis of more complex molecules

Potential drug candidate

A compound that has the potential to be developed into a new drug

Specific properties

Characteristics that define the compound's behavior and reactivity

Potential biological activities

The compound's possible effects on biological systems, such as its ability to interact with proteins or enzymes

Ongoing research and investigation

Continuous efforts to study and understand the properties and potential uses of the compound.

Upstream product

• 101349-12-6 2-(5-fluoro-1H-indol-3-yl)ethanol 
• 443-73-2 (5-fluoroindol-3-yl)acetic acid 
• 823-85-8 4-fluorophenyhydrazine hydrochloride 

Downstream Products

• 781590-91-8 2-benzyl-8-<2-(5-fluoro-1H-indol-3-yl)ethyl>-2,8-diazaspiro<4.5>decan-3-one 
• 169206-53-5 3-benzyl-8-<2-(5-fluoro-1H-indol-3-yl)ethyl>-1-oxa-3,8-diazaspiro<4.5>decan-2-one 
• 1487273-57-3 5-fluoro-3-(2-(4-((2,3-dihydro-2-phenylbenzo[b][1,4]dioxin-3-yl)methyl)piperazin-1-yl)ethyl)-1H-indole 

Relevant articles and documents

Synthesis and antidepressant effect of novel aralkyl piperazine and piperidine derivatives targeting SSRI/5-HT1A/5-HT7

A series of novel aralkyl piperazine and piperidine derivatives were synthesized, and evaluated for their serotonin reuptake inhibitory and 5-HT1A/5-HT7 receptors affinities activity. Antidepressant activities in vivo of the selective compound were screened using the forced swimming test (FST) and tail suspension test (TST). The results indicated that compound 19a exhibited high affinities for the 5-HT1A/5-HT7 receptors (5-HT1A, Ki = 12 nM; 5-HT7, Ki = 3.2 nM) coupled with potent serotonin reuptake inhibition (IC50 = 14 nM) and showed a marked antidepressant-like effect in the FST and TST models.

Constructing iboga alkaloids via C-H bond functionalization: Examination of the direct and catalytic union of heteroarenes and isoquinuclidine alkenes

The iboga alkaloids have attracted considerable attention in both the scientific community and popular media due to their reported ability to reverse or markedly diminish cravings for, and self-administration of, the major drugs of abuse. We have developed three new intramolecular C-H functionalization procedures leading to the core seven-membered ring of the iboga skeleton, a cyclization that proved to be highly challenging. The electrophilic palladium salt Pd(CH3CN)4(BF4)2 was effective for the cyclization of diverse N-(2-arylethyl)isoquinuclidines with yields of 10-35%. A two-step, bromination-reductive Heck reaction protocol was also effective for the synthesis of ibogamine in 42% yield. Finally, a direct Ni(0)-catalyzed C-H functionalization provided the benzofuran analogues of ibogamine (74%) and epi-ibogamine (38%). Although each approach suffers from significant shortcomings, in combination, the methods described provide practical routes to diverse ibogamine analogues.

SMALL MOLECULE INDUCERS OF GDNF AS POTENTIAL NEW THERAPEUTICS FOR NEUROPSYCHIATRIC DISORDERS

The invention provides a compound having the structure (I), wherein A is a substituted or unsubstituted ring; Z is present or absent and when present is (II), wherein n is 0, 1, 2, 3, or 4; Y is -(CR11R12)-, -NH(CR11R12)- or -O(CR11R12)- wherein R11 and R12 are each hydrogen or combine to form a carbonyl; and wherein R1 to R10 are herein as described.